Xenon Pharmaceuticals Inc. (NASDAQ: XENE) stock gains by 79.80% during the current market trading session. Xenon Pharmaceuticals is a clinical-stage pharmaceutical business dedicated to discovering novel medicines to help people with neurological diseases live better lives. With an emphasis on epilepsy, they are developing a new product pipeline of neurology treatments to target regions of high unmet medical need.
XENE stock’ Current Update
Xenon Pharmaceuticals announced encouraging topline findings from the Phase 2b X-TOLE clinical study, which assessed the clinical effectiveness, safety, and tolerability of XEN1101 – a differentiated Kv7 potassium channel modulator – in adult patients with focal epilepsy as an adjunctive therapy.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
When compared to placebo, XEN1101 showed a substantial and dosage-dependent reduction in monthly (defined as 28 days) focal seizure frequency (monotonic dose-response; p0.001), which satisfied the trial’s primary effectiveness objective. A pairwise assessment of each active dosage to placebo and a responder evaluation with the proportion of patients who obtained a 50% or higher decrease in monthly focal seizure frequency from baseline were included as additional main and secondary endpoints.
Dr. Christopher Kenney, Xenon’s Chief Medical Officer stated,
He wants to thank the patients, investigators, and site coordinators who took part in the X-TOLE research on behalf of the whole Xenon team. They have gathered solid evidence to demonstrate XEN1101’s effectiveness, safety, and tolerability, as well as a strongly positive product profile. Importantly, across all dosage groups, they found statistically significant decreases in focal onset seizures compared to placebo, suggesting that it is very active in the central nervous system. They are excited to collaborate with the FDA to prepare for an accelerated development route in the future, based on these promising topline results.
Xenon plans to continue designing the future clinical development of XEN1101 with assistance from the US Food and Drug Administration and other regulatory bodies. Furthermore, the three-year X-TOLE open-label extension is anticipated to provide crucial long-term data for XEN1101.